Hormone Therapy — HRT (Women) and TRT (Men)

Verdict: HRT in women: Probable when started ≤age 60 / within 10 years of menopause; Mixed when initiated late. TRT in men with documented hypogonadism: Probable; in eugonadal men "for longevity": Suggestive.

Last reviewed: 2026-04-25 Triangulated against anchor: Statins (population-stratified) — hormone therapy follows a similar timing/population-specific pattern

TL;DR

The 2002 WHI early-stop story dominated public perception of HRT for two decades and substantially overstated harm in younger menopausal women. Long-term follow-up (20-year WHI, 2024) and modern timing-stratified analyses show all-cause mortality reduction with HRT initiated before age 60 / within 10 years of menopause. Estrogen monotherapy in hysterectomized women shows additional protective signals. TRT (TRAVERSE 2023, n=5,246) cleared its CV-safety hurdle in hypogonadal men. Both hormones are population- and timing-specific tools, not universal longevity drugs.

What it is

HRT (women, post-menopause):

• Estrogen alone (for hysterectomized women) or estrogen + progestogen (for women with intact uterus)
• Routes: oral, transdermal patch/gel, vaginal (local)
• Bioidentical (estradiol, micronized progesterone) increasingly preferred over conjugated equine estrogens + medroxyprogesterone (the WHI formulations)

TRT (men, hypogonadism):

• Testosterone gel, injection (intramuscular, subQ), pellets
• Indication: documented hypogonadism (low total/free testosterone + symptoms)
• Off-label longevity / wellness use is increasingly common but evidence-thin

Proposed mechanism

Estrogen:

• Vasoprotective (endothelial function, lipid profile improvements)
• Bone density preservation
• Reduced vasomotor symptoms (the symptomatic indication)
• Possible neuroprotective effects (cognitive aging, dementia debate ongoing)
• Maintains tissue-level homeostasis lost at menopause

Testosterone:

• Maintains muscle mass, bone density, libido, mood, hematocrit
• Cardiovascular effects historically debated; TRAVERSE largely settled the safety question

Confidence: Established for many individual mechanisms; Plausible for the broader "delaying systemic aging" framing.

Evidence ladder

Animal models (T3-T4)

Hormone-replacement studies in oophorectomized/orchiectomized rodents show clear bone, metabolic, vascular benefits. Lifespan effects modest and context-dependent.

Human (T1)

HRT in women:

• WHI (2002 NEJM, primary stop) — combined HRT (CEE+MPA) in older women (mean age 63) showed increased breast cancer, stroke, VTE; the trial was stopped early. This dominated public discourse for years.
• WHI long-term follow-up (Manson 2017 JAMA, 20-year follow-up 2024) — when re-analyzed by age and time since menopause, women starting HRT before age 60 / within 10 years of menopause showed all-cause mortality benefit. The "timing hypothesis" is now widely accepted.
• Estrogen-only WHI arm — in hysterectomized women, estrogen-only therapy showed lower breast cancer incidence and mortality, lower CHD in younger initiators.
• Use of estrogen monotherapy beyond age 65 (Menopause 2024) — observational, but large; significant reductions in mortality (19%), breast cancer (16%), CHF, AMI, dementia.
• KEEPS, ELITE — biomarker-focused RCTs in younger initiators consistent with timing hypothesis.

TRT in men:

• TRAVERSE (Lincoff 2023, NEJM) — n=5,246 hypogonadal men with CV risk factors. Testosterone vs placebo, ~33-month follow-up. Non-inferior on MACE; no increased prostate cancer. Settled the CV-safety question for hypogonadal men with established CV risk.
• T-Trials (Snyder 2016 NEJM) — modest benefits on sexual function, mood, anemia, bone density in older hypogonadal men.
• No mortality RCT in eugonadal men taking testosterone "for longevity"; this population is essentially un-trialed.
• Observational data in eugonadal men is mixed and confounded.

Population caveats

The decisive evidence is for:

• Symptomatic women in early menopause (HRT for symptoms; longevity benefit appears as a co-effect)
• Hysterectomized women (estrogen-only, more favorable risk profile)
• Hypogonadal men with documented low testosterone (TRT; CV-safety established)

It is not for:

• Lean, eugonadal men using TRT off-label for longevity / performance (no RCT support for benefit; suppresses endogenous production; fertility implications)
• Women starting HRT 15+ years post-menopause (timing hypothesis says benefit attenuates / inverts)

Confounds

• WHI 2002's age confound dominated discourse for 20 years; the timing-stratified re-analyses are essentially correcting that misframing.
• Healthy-user effect in observational HRT data is large.
• Formulation matters — WHI used CEE+MPA; modern bioidentical formulations have different risk profiles, and direct head-to-head trials are limited.
• TRT in eugonadal men — population not represented in any major mortality trial.
• Combined-progestogen breast cancer signal is real for older women initiating CEE+MPA; not as clear for modern micronized progesterone.

Conflict of interest scan

• WHI was NIH-funded; long-term follow-up academic. No discount.
• TRAVERSE was AbbVie-funded but pre-registered, FDA-grade — minimal effective discount.
• TRT and HRT industries are large and produce some advocacy literature; the major RCT evidence is independent.

Human translation

Honest decomposition:

1. For women in early menopause with symptoms or risk factors: HRT is well-supported on a benefit-risk basis when initiated within ~10 years of menopause / before age 60. Probable verdict.
2. For asymptomatic women initiating HRT 15+ years post-menopause for longevity: the timing hypothesis suggests reduced or inverted benefit; evidence is weaker, risk profile less favorable.
3. For men with documented hypogonadism and symptoms: TRT is supported, CV-safety established by TRAVERSE. Probable verdict.
4. For eugonadal men supplementing testosterone for longevity / performance: no trial evidence; substantial suppressive effects on endogenous production; unsupported by methodology standards.
5. For estrogen-only therapy in hysterectomized women: the evidence is favorable enough that this may be one of the more underappreciated longevity-relevant clinical interventions in older women.

Calibrated verdict

Population- and timing-stratified:

• Probable for HRT initiated ≤age 60 / within 10 years of menopause.
• Mixed for HRT initiated late (>10 years post-menopause) or formulation/regimen choice debated.
• Probable for TRT in documented hypogonadism (TRAVERSE-like population).
• Suggestive for TRT in eugonadal men "for longevity."

Compared to statins (Strong/Probable/Mixed by population), hormone therapy follows a parallel structure: powerful intervention for the right population/timing, weak or absent evidence for general "longevity supplementation" framing.

Confidence interval on verdict

• HRT timing hypothesis is well-established and unlikely to move much.
• TRT-in-eugonadal-men could move to Probable if specific aging-endpoint trials (in progress) read positive; could also stay Suggestive.
• Most likely 2-year trajectory: stable; modest evolution as more bioidentical-specific data accumulates.

Open questions

• Q: For women initiating HRT in their 40s prophylactically (perimenopause), what is the risk-benefit on long-term mortality?
• Q: Does transdermal estradiol + micronized progesterone (modern formulation) show the same risk profile as oral CEE+MPA, or is it meaningfully different on VTE / breast cancer?
• Q: For eugonadal men with declining-but-not-low testosterone (the "T optimization" population), is there any aging benefit, and does it outweigh suppression of endogenous production?
• Q: For trans men and women on long-term cross-sex hormone therapy, what is the longevity / aging trajectory?

Sources

• Manson et al. 2017, JAMA — Menopausal HT and long-term all-cause and cause-specific mortality (WHI)
• WHI 20-year follow-up summary, 2024 — decreased all-cause mortality with HRT initiated <60
• Use of menopausal hormone therapy beyond age 65, Menopause 2024
• Menopausal HRT and reduction of all-cause mortality and CVD: timing hypothesis (PMC9178928)
• Mukherjee — Update on Menopause Hormone Therapy: indications and unanswered questions, Clin Endocrinol 2024
• Lincoff et al. 2023, NEJM — TRAVERSE: cardiovascular safety of testosterone in middle-aged and older men with hypogonadism
• Menopausal HT — risks, benefits, emerging options: narrative review (PMC12652300, 2024)

Produced under methodology locked 2026-04-24. Triangulated against statins (population-stratified pattern).